1) Goh SK, Yang KY, Koh JSB, et al:Subtrochanteric insufficiency fractures in patients on alendronate therapy. J Bone Joint Surg Br 89:349-53, 2007
2) 伊東昌子:骨梁構造と骨力学特性についての最近の知見.整形外科55:833-41,2004
3) 伊東昌子:骨質の定量評価と薬物による改善.生体医工学44:496-502,2006
4) 伊東昌子:ビスホスホネート治療の骨構造特性への影響.Clin Calcium 19:20-29,2009
5) Lenard BA, Lorich DG, Lane JM:Atypical fractures of the femoral diaphisis in postmenopausal women taking alendronate. N Engl J Med 358:13-4-6, 2008
6) Mashiba T, Hirano T, Turner CH et al:Suppressed bone turnover by bisphosphonate increases microdamage accumulation and reduces some biomechanical properties in dog rig. J Bone Miner Res 15:613-20, 2000
7) 真柴 賛,森 諭史:骨吸収抑制剤と骨折治癒.Clin Calcium 19:65-71,2009
8) Peter CP, Cook O, Nunamaker DM, et al:Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14:74-79, 1996
9) Schneider JP:Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatics 61:31-33, 2006
10) Schneider JP:Bisphosphonates and low-impact femoralfractures:Current evidence on alendronate-fracture risk. Geriatcis 64:18-23, 2009
11) Sayed-Noor AS, Sjoden GO:Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy―a case report. Acta Orthopedica 79:565-567, 2008
12) 谷口 充,塩出速雄,坂本 啓・他:ビスホスホネート服用患者に認められた非定型的な大腿骨骨幹部骨折の3症例.中部整災誌52:661-662,2009
13) Updated on bisphosphonats FDA-Approved for prevention and treatment of osteoporosis. July 2008. National Osteoporosis Foundation web site. http://www.nof.org.CUOnline-July08-forweb.pdf.